12:00 AM
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Everolimus regulatory update

Novartis amended an sNDA for everolimus and is now seeking approval for treatment of advanced neuroendocrine tumors of pancreatic origin. The company was previously seeking approval to treat advanced neuroendocrine tumors of gastrointestinal, lung or...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >